A Case Series of Refractory Cutaneous Sarcoidosis Successfully Treated with Infliximab
Sarcoidosis is a systemic granulomatous disease of unknown cause. The management of sarcoidosis remains problematic. Systemic and topical corticosteroids are the mainstay of therapy but may cause unacceptable side effects. Biologic therapies, such as infliximab, have recently been proposed as another treatment option for cutaneous sarcoidosis.
The authors describe three patients who were diagnosed with cutaneous sarcoidosis with systemic involvement. All of the patients were refractory to conventional therapies but responded to infliximab therapy.
Infliximab is an alternative medication for refractory sarcoidosis that has a relatively benign side-effect profile. However, definite indications, dosage, interval, and duration of treatment for cutaneous sarcoidosis are not firmly established.
- A Case Series of Refractory Cutaneous Sarcoidosis Successfully Treated with Infliximab
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Dermatology and Therapy
- Online Date
- July 2012
- Print ISSN
- Online ISSN
- Springer Healthcare Communications
- Additional Links
- Tumor necrosis factor inhibitor
- Industry Sectors
- Author Affiliations
- 1. Department of Dermatology, University of Maryland School of Medicine, 419 W. Redwood Street, Suite 240, Baltimore, MD, 21201, USA
- 2. Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand